TrialJournal of Crohn's & colitis2021

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.

Marc Ferrante et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.